X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (313) 313
adult (193) 193
hematology (184) 184
female (172) 172
male (171) 171
middle aged (162) 162
bone marrow transplantation (160) 160
oncology (127) 127
adolescent (123) 123
transplantation (104) 104
child (102) 102
immunology (78) 78
child, preschool (73) 73
animals (68) 68
combined modality therapy (63) 63
whole-body irradiation (60) 60
acute disease (54) 54
dogs (53) 53
transplantation, homologous (53) 53
aged (52) 52
graft vs host disease - prevention & control (47) 47
transplantation, autologous (45) 45
cyclophosphamide - therapeutic use (44) 44
treatment outcome (43) 43
prognosis (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
hematopoietic stem cell transplantation (37) 37
recurrence (37) 37
time factors (36) 36
graft vs host disease - etiology (34) 34
remission induction (33) 33
cyclophosphamide - administration & dosage (32) 32
follow-up studies (32) 32
leukemia (32) 32
infant (31) 31
survival rate (31) 31
survival analysis (30) 30
acute myeloid-leukemia (29) 29
bone marrow transplantation - adverse effects (28) 28
bone-marrow transplantation (28) 28
leukemia - therapy (28) 28
cyclophosphamide (27) 27
retrospective studies (26) 26
therapy (26) 26
bone marrow transplantation - immunology (25) 25
disease-free survival (25) 25
index medicus (25) 25
acute myelogenous leukemia (24) 24
chemotherapy (24) 24
versus-host disease (24) 24
anemia, aplastic - therapy (23) 23
bone marrow transplantation - methods (23) 23
cyclosporine (22) 22
leukemia, myeloid - therapy (22) 22
clinical trials as topic (21) 21
lymphoma - therapy (21) 21
histocompatibility testing (20) 20
antibodies, monoclonal - therapeutic use (19) 19
colony-stimulating factor (19) 19
blood transfusion (18) 18
busulfan - administration & dosage (18) 18
graft survival (18) 18
leukemia, myeloid, acute - therapy (18) 18
recombinant proteins - therapeutic use (18) 18
total-body irradiation (18) 18
hematopoietic stem cells (17) 17
host-disease (17) 17
methotrexate (17) 17
methotrexate - therapeutic use (17) 17
research (17) 17
risk factors (17) 17
surgery (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
busulfan (16) 16
care and treatment (16) 16
cyclophosphamide - adverse effects (16) 16
drug therapy, combination (16) 16
graft rejection (16) 16
age factors (15) 15
cytarabine - administration & dosage (15) 15
drug administration schedule (15) 15
leukemia - surgery (15) 15
leukemia, myeloid, acute - drug therapy (15) 15
leukemia, myeloid, acute - mortality (15) 15
medicine, general & internal (15) 15
whole-body irradiation - adverse effects (15) 15
bone marrow (14) 14
bone marrow - radiation effects (14) 14
cells (14) 14
chronic myelogenous leukemia (14) 14
cyclosporins - therapeutic use (14) 14
health aspects (14) 14
leukemia, myeloid - drug therapy (14) 14
lymphoma, non-hodgkin - therapy (14) 14
prospective studies (14) 14
radiotherapy dosage (14) 14
toxicity (14) 14
trial (14) 14
antineoplastic agents - therapeutic use (13) 13
busulfan - adverse effects (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 7, p. 1113
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2001, Volume 19, Issue 13, pp. 3244 - 3254
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 2010, Volume 24, Issue 5, pp. 909 - 913
Recent whole-genome sequencing efforts led to the identification of IDH1(R132) mutations in acute myeloid leukemia (AML) patients. We studied the prevalence... 
NPM | FLT3 | Acute myeloid leukemia | Isocitrate dehydrogenase | IDH1 | Pediatric AML | GLIOMAS | isocitrate dehydrogenase | ADULTS | ACUTE MYELOID-LEUKEMIA | CYTARABINE | TUMORS | CODON 132 | THERAPY | acute myeloid leukemia | ONCOLOGY | pediatric AML |